Announcing the ICIS-LUMINEX John R. Kettman Award for Excellence in Interferon & Cytokine Research

Nomination Submission Deadline for the 2023 Award: March 6, 2023

This award generously supported by Luminex Corporation recognizes a mid-career investigator who has made outstanding contributions to the field of interferon or cytokine biology.  The awardee will receive a $5,000 cash prize that covers meeting registration, and where applicable travel support to the ICIS annual meeting for presentation of his or her research in an award lecture. The award is named after Dr. John R (Jack) Kettman, an immunologist who was instrumental in the development of Luminex’s technologies and the Luminex Corporation.

A nominee must be an ICIS member in good standing* who is within 15 years from their terminal degree (Ph.D., M.D., or equivalent). A nominee must be an independent research scientist (PI); postdoctoral fellows are not eligible. Eligibility of the nominee will be checked at time of nomination and before presentation of award. 

  • Letters of nomination should be sent to the ICIS President via the Submission Form. The nomination package should include a full CV of the nominee and a letter of nomination detailing the accomplishments of the nominee and reasons for the nomination. A candidate may be nominated by more than one ICIS member.

It should be noted that the awardees will be judged based on the following criteria which should be included in the nomination letter:

  • outstanding publications and ground-breaking discoveries in the field
  • collective contributions to the field of cytokine biology 

* Member dues paid through the end of 2023.

# This award is intended for a mid-career researcher with a maximum of 15 years post-degree. It is, however, recognized that there may have been family-related, personal, or other circumstances resulting in extended time out of the laboratory. Exceptions to the 15-year limit will be considered based on a description of any special circumstances. Please email  with inquiries.

Dr. Kettman received his undergraduate degree in biochemistry at the University of California, Berkeley, and completed his Ph. D. at Oregon State University under the advisory of TE King.  He completed his postdoctoral work in immunochemistry with E. Benjamini  and immunobiology with RW Dutton. He was a member of the Basel Institute for Immunology 1972-1973 and spent twenty eight years as on the faculty of the Microbiology Department at University of Texas Southwestern Medical School in Dallas, Texas. He currently serves as a Professor Emeritus in the Department of Immunology, at the University of Texas Southwestern Medical School at Dallas. Jack was a co-founder of Luminex Corporation and former member of Board of Directors (1995) and a partner and member of board of Directors, Radix BioSolutions, Georgetown TX. He is author or co-author of over one hundred publications in reviewed scientific Journals. 

author avatar
joefner@cytokinesociety.org